OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Psychopharmacology is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up	161
Ketamine: A tale of two enantiomers	104
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science	97
Pivotal mental states	70
Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD	65
Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca	63
Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis	56
Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin	55
First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder	55
A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers	51
Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium	50
Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches	50
Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience	49
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review	48
Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial	41
Associations between lifetime classic psychedelic use and markers of physical health	41
Ketamine’s effect on inflammation and kynurenine pathway in depression: A systematic review	40
Acute subjective effects in LSD- and MDMA-assisted psychotherapy	40
Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans	39
Psychedelics and health behaviour change	38
The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration an	38
Does cannabis complement or substitute alcohol consumption? A systematic review of human and animal studies	38
Modulation of microglial activation by antidepressants	37
Dose–response relationships of psilocybin-induced subjective experiences in humans	36
Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial	35

Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology	33
A qualitative and quantitative account of patient’s experiences of ketamine and its antidepressant properties	33
Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study	32
Assessment of cognitive and psychomotor impairment, subjective effects, and blood THC concentrations following acute administration of oral and vaporized cannabis	32
Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action	31
The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects	30